Biogen Idec Above Average Volume

Hewlett Packard (HPQ)

Dell (DELL)

Facebook (FB)

Apple (AAPL)

Goldman Sachs (GS)

Fred's First Quarter 2012 EPS Increase 17%

Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook

Best ETFs For Facebook Exposure

McDonald's Announces Quarterly Cash Dividend

Is KB HOME Closing in to Resistance?

Biogen Idec Above Average Volume

Published on Wednesday, 01 February 2012 11:38 Written by Christopher Lynn

biib New York, February 1st (TradersHuddle.com) - Unusual high volume detected on shares of Biogen Idec Inc. (NASDAQ:BIIB), early in the trading session. Biogen Idec is currently trading higher by 1.18%, so definitely the buyers stepping in, as the stock's volume is already above average.

Biogen Idec Inc. (NASDAQ:BIIB) develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The products from the biotechnology company addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis. The company was founded in 1985 and is based in

Biogen Idec has already traded 1.433 times its 3-month average volume, and has calculated support and resistance at $109.52 and $119.56 respectively. Traders like to use volume as their lie detector for price action moves through predefined trading ranges.

The overall market index S&P 500 is trading higher by 1% from its previous trading close, which means that Biogen Idec stock is outperforming the overall market.